Eli Lilly prepares for as many as 5 new drug launches next year

Reuters

Published Dec 13, 2022 06:57AM ET

Updated Dec 13, 2022 02:06PM ET

Eli Lilly prepares for as many as 5 new drug launches next year

By Leroy Leo

(Reuters) -Eli Lilly and Co said on Tuesday it hopes to launch as many as five new treatments next year that could drive growth through the decade as it bets on multi-billion dollar markets for treating obesity and Alzheimer's disease.

The drugmaker is spending heavily on marketing and research and development as it prepares for data release and potential approvals for two keenly watched drugs next year, donanemab for Alzheimer's and tirzepatide for obesity.

The higher spending led Lilly to forecast 2023 profit below analysts' estimates and its shares fell about 1% to $363.59. The company's shares have been up about 31% this year.

Tirzepatide received the U.S. health regulator's approval for type 2 diabetes this year and is sold under the brand name Mounjaro.

Lilly expects its marketing and related expenses to be between $6.9 billion and $7.1 billion in 2023, $500 million higher than this year.

"I think we see two of them as kind of generational opportunities, tirzepatide for obesity and donanemab, and the other three as being great opportunities in very competitive spaces," Lilly Chief Executive David Ricks said.

The other three treatments are mirikizumab for a type of inflammatory bowel disease, lebrikizumab for atopic dermatitis and cancer drug pirtobrutinib.

The company also plans to spend between $8.2 billion and $8.4 billion for research and development next year.

Lilly expects revenue between $30.3 billion and $30.8 billion for 2023, higher than Wall Street estimates of $30.12 billion, according to Refinitiv IBES data.

© Reuters. FILE PHOTO: FILE PHOTO: An Eli Lilly and Company pharmaceutical manufacturing plant is pictured at 50 ImClone Drive in Branchburg, New Jersey, March 5, 2021.  REUTERS/Mike Segar/File Photo

The company forecast 2023 adjusted profit per share of $8.10 to $8.30, lower than analysts' estimates of $9.15.

Lilly expects no sales from its COVID-19 antibody drugs after the U.S. Food and Drug Administration pulled authorization for its therapy bebtelovimab last month.

Get The News You Want
Read market moving news with a personalized feed of stocks you care about.
Get The App

Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.

Sign out
Are you sure you want to sign out?
NoYes
CancelYes
Saving Changes